Blog
RSS FeedPosted by Michael Wonder on 20 Oct 2015
Nivolumab in melanoma: added benefit in certain patients says German IQWIG
15 October 2015 - IQWiG has found there is a survival advantage for nivolumab in treatment-naive patients with BRAF V600 ...
Posted by Michael Wonder on 15 Oct 2015
Nivolumab in melanoma: additional clinical benefit in a certain patient population according to the IQWiG
15 October 2015 - Nivolumab (Opdivo) has been approved since June 2015 for use by adults with advanced melanoma. The Institute ...
Posted by Michael Wonder on 15 Oct 2015
Belatacept after kidney transplantation: indication of an significant added benefit says IQWiG
15 October 2015 - Belatacept (Nulojix) has been approved since June 2011 for use by adults after a kidney transplant. Together ...
Posted by Michael Wonder on 09 Oct 2015
IQWiG publishes English translation of the new version of its General Methods
8 October 2015 - The English translation of the new version of the methods paper (General Methods 4.2) by the German ...
Posted by Michael Wonder on 06 Oct 2015
Ceritinib in advanced lung cancer: no hint of added benefit
6 October 2015 - The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults ...
Posted by Michael Wonder on 01 Oct 2015
Ceritinib in advanced lung cancer: no evidence of additional benefits says IQWiG
1 October 2015 - Ceritinib (Zykadia) has been available since May 2015 for the treatment of adult patients with non small-cell ...
Posted by Michael Wonder on 17 Sep 2015
Lomitapide mesylate in hypercholesterolaemia: IQWiG finds no hint of added clinical benefit (English version)
15 September 2015 - Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous ...
Posted by Michael Wonder on 16 Sep 2015
German drug companies are criticised for not focusing on useful therapeutic areas
15 September 2015 - A 2011 German law designed to lower prices of new innovative drugs has not been as successful ...
Posted by Michael Wonder on 15 Sep 2015
Lomitapide mesylate for hypercholesterolemia: no evidence of additional benefits
15 September 2015 - Lomitapide mesylate (trade name Lojuxta) has been approved since July 2013 for use by adults with homozygous ...
Posted by Michael Wonder on 07 Sep 2015
IQWiG invites to its Autumn Symposium 2015
7 September 2015 - Benefit assessments of medical interventions are conducted to answer the question: What is the benefit and possible ...
Posted by Michael Wonder on 01 Sep 2015
Secukinumab with plaque psoriasis: manufacturer dossier provides no evidence of an additional clinical enefit according to the IQWiG
1 September 2015 - Secukinumab (Cosentyx) was approved for use by adults with moderate to severe plaque psoriasis (psoriasis) in January ...
Posted by Michael Wonder on 20 Aug 2015
Afatinib: added benefit in certain mutations confirmed by IQWiG
17 August 2015 - Afatinib dimaleate (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients ...
Posted by Michael Wonder on 19 Aug 2015
Safinamide in Parkinson disease: no hint of added benefit says IQWiG
17 August 2015 - Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of ...
Posted by Michael Wonder on 05 Aug 2015
Aclidinium bromide/formoterol in COPD: added benefit for certain patient groups
The fixed-dose combination aclidinium bromide/formoterol has been approved since November 2014 for long-term treatment of adults with chronic obstructive pulmonary ...
Posted by Michael Wonder on 05 Aug 2015
Aflibercept in diabetic macular oedema: added benefit not proven
Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular ...